A Vaccine against Rotavirus — When is Too Much Too Much?

Publisher Website
Google Scholar
Abstract
The development of the quadrivalent rotavirus vaccine evaluated in the study by Pérez-Schael et al., reported in this issue of the Journal, 1 represents the culmination of a long and highly creative process of research and development at the National Institutes of Health.2 Today, just 25 years after rotavirus was discovered,3 the use of a modified Jennerian approach has resulted in a quadrivalent vaccine that combines a naturally attenuated serotype 3 rhesus rotavirus with reassortants composed of 10 genomic segments of rhesus rotavirus RNA plus 1 of human origin encoding the VP7 neutralization specificity of serotype 1, 2, or 4 rotavirus. . . .